Borrelidin, a small molecule nitrile-containing macrolide inhibitor of threonyl-tRNA synthetase, is a potent inducer of apoptosis in acute lymphoblastic leukemia

Investigational New Drugs

Volumn 30, Issue 4, 2012, Pages 1361-1370

  Habibi, Darya ^a   Ogloff, Nadya ^a   Jalili, Reza B ^a   Yost, Arla ^b   Weng, Andrew P ^b   Ghahary, Aziz ^a   Ong, Christopher J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Acute lymphoblastic leukemia; ALL cell lines; Borrelidin; CHOP. Apoptosis; GCN2 kinase pathway

Indexed keywords

BORRELIDIN; GENERAL CONTROL NONDEREPRESSIBLE 2 KINASE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; PHOSPHOTRANSFERASE; THREONINE TRANSFER RNA LIGASE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN CEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVATION; FIBROBLAST; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; NEWBORN; PRIORITY JOURNAL; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; ENZYME INHIBITORS; FATTY ALCOHOLS; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MACROLIDES; NITRILES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; THREONINE-TRNA LIGASE; TRANSCRIPTION FACTOR CHOP;

EID: 84866732814     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9700-y     Document Type: Article

References (37)

1. Jabbour EJ, Faderl S, Kantarjian HM. (2005) Adult acute lymphoblastic leukemia. Mayo Clin Proc 80(11):1517-1527
2. Pieters R, Carroll WL. (2008) Biology and treatment of acute lymphoblastic leukemia. Pediatr Clin North Am 55(1):1-20, ix
3. Crazzolara R, Bendall L. (2009) Emerging treatments in acute lymphoblastic leukemia. Curr Cancer Drug Targets 9(1):19-31
4. Avramis VI, Tiwari PN. (2006) Asparaginase. (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomedicine 1(3):241-254
5. Pui CH, Evans WE. (1998) Acute lymphoblastic leukemia. N Engl J Med 339(9):605-615
6. Pui CH, Evans WE. (2006) Treatment of acute lymphoblastic leukemia. N Engl J Med 354(2):166-178
7. Douer D. (2008) Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia? Best Pract Res Clin Haematol 21(4):647-658
8. Ascierto PA et al. (2005) Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 23(30):7660-7668
9. Cheng PN et al. (2007) Pegylated recombinant human arginase. (rhArg-peg5, 000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 67(1):309-317
10. Bunpo P et al. (2009) GCN2 protein kinase is required to activate amino acid deprivation responses in mice treated with the anti-cancer agent L-asparaginase. J Biol Chem 284. (47):32742-32749
11. Reinert RB et al. (2006) Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem 281(42):31222-31233
12. Anthony TG et al. (2004) Preservation of liver protein synthesis during dietary leucine deprivation occurs at the expense of skeletal muscle mass in mice deleted for eIF2 kinase GCN2. J Biol Chem 279(35):36553-36561
13. Crosby JS et al. (2000) Regulation of hemoglobin synthesis and proliferation of differentiating erythroid cells by heme-regulated eIF-2alpha kinase. Blood 96(9):3241-3248
14. Harding HP et al. (2000) Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell 6. (5):1099-1108
15. Jiang HY et al. (2004) Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response. Mol Cell Biol 24(3):1365-1377
16. Munn DH et al. (2005) GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2, 3-dioxygenase. Immunity 22(5):633-642
17. Kawamura T et al. (2003) Anti-angiogenesis effects of borrelidin are mediated through distinct pathways: threonyl-tRNA synthetase and caspases are independently involved in suppression of proliferation and induction of apoptosis in endothelial cells. J Antibiot. (Tokyo) 56(8):709-715
18. Nagamitsu T et al. (2007) Total synthesis of borrelidin. J Org Chem 72(8):2744-2756
19. Habibi D et al. (2010) High expression of IMPACT protein promotes resistance to indoleamine 2, 3-dioxygenase-induced cell death. J Cell Physiol 225(1):196-205
20. Jalili RB et al. (2009) Mouse pancreatic islets are resistant to indoleamine 2, 3 dioxygenase-induced general control nonderepressible-2 kinase stress pathway and maintain normal viability and function. Am J Pathol 174(1):196-205
21. Forouzandeh F et al. (2008) Skin cells, but not T cells, are resistant to indoleamine 2, 3-dioxygenase. (IDO) expressed by allogeneic fibroblasts. Wound Repair Regen 16(3):379-387
22. Ghahary A et al. (2005) Differentiated keratinocyte-releasable stratifin. (14-3-3 sigma)' stimulates MMP-1 expression in dermal fibroblasts. J Invest Dermatol 124(1):170-177
23. Medyouf H et al. (2010) Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood 115(6):1175-1184
24. Armstrong F et al. (2009) NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. Blood 113(8):1730-1740
25. Ertel IJ et al. (1979) Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Childrens Cancer Study Group. Cancer Res 39(10):3893-3896
26. Funahashi Y et al. (1999) Establishment of a quantitative mouse dorsal air sac model and its application to evaluate a new angiogenesis inhibitor. Oncol Res 11(7):319-329
27. Sauerborn M et al. (2010) Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci 31(2):53-59
28. Adluri S et al. (1995) Immunogenicity of synthetic TF-KLH. (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol Immunother 41. (3):185-192
29. Chirino AJ, Ary ML, Marshall SA. (2004) Minimizing the immunogenicity of protein therapeutics. Drug Discov Today 9. (2):82-90
30. Ghahary A et al. (2004) Expression of indoleamine 2, 3-dioxygenase in dermal fibroblasts functions as a local immunosuppressive factor. J Invest Dermatol 122(4):953-964
31. Forouzandeh F et al. (2008) Differential immunosuppressive effect of indoleamine 2, 3-dioxygenase. (IDO) on primary human CD4+ and CD8+ T cells. Mol Cell Biochem 309(1-2):1-7
32. Li Y, Tredget EE, Ghahary A. (2004) Cell surface expression ofMHC class I antigen is suppressed in indoleamine 2, 3-dioxygenase genetically modified keratinocytes: implications in allogeneic skin substitute engraftment. Hum Immunol 65(2):114-123
33. Tsuchiya E et al. (2010) A novel method of screening cell-cycle blockers as candidates for anti-tumor reagents using yeast as a screening tool. Biosci Biotechnol Biochem 74(2):411-414
34. Hao S et al. (2005) Uncharged tRNA and sensing of amino acid deficiency in mammalian piriform cortex. Science 307(5716): 1776-1778
35. Ye J et al. (2010) The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. EMBO J 29(12):2082-2096
36. Wek RC, Staschke KA. (2010) How do tumours adapt to nutrient stress? EMBO J 29(12):1946-1947
37. Jiang HY, Wek RC. (2005) Phosphorylation of the alpha-subunit of the eukaryotic initiation factor-2. (eIF2alpha)' reduces protein synthesis and enhances apoptosis in response to proteasome inhibition. J Biol Chem 280(14):14189-14202